CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 16 | 1 | −15 |
| Shares | 1.25M | 228 | −1.25M (−100.0%) |
| Value | $1.06M | $25 | −$1.06M (−100.0%) |
New holders (0)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
None.
Sold out (15)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| VR Adviser, LLC | 987,259 | $839.2K |
| Woodline Partners LP | 133,406 | $113.4K |
| Renaissance Technologies LLC | 43,100 | $36.6K |
| Two Sigma Investments, LP | 23,787 | $20.2K |
| Bank of America Corp | 19,935 | $16.9K |
| Geode Capital Management, LLC | 18,808 | $16.0K |
| Citadel Advisors LLC | 14,045 | $11.9K |
| Royal Bank of Canada | 9,950 | $8.00K |
| UBS Group AG | 659 | $560 |
| Wells Fargo & Company | 505 | $429 |
| Morgan Stanley | 367 | $312 |
| BNP Paribas Arbitrage, SA | 134 | $114 |
| JPMorgan Chase & Co | 25 | $21 |
| Colonial Trust Co | 11 | $9 |
| MAI Capital Management | 5 | $5 |